Keyword: Nektar Therapeutics
Nektar has had a mixed few months as data fed through for its lead cancer drug NKTR-214, but new data in bladder cancer should help longer term
As we near the end of the year, we take a look back over the biggest stories of 2018 and gauge what readers found the most interesting.
Dermavant hires Zavodnick as CEO; Bayer VP to lead Matoke Pharma; and Genentech I-O leader Wei Lin will head up Nektar's oncology work.
Nektar Therapeutics poached Genentech immunotherapy leader Wei Lin to head up its oncology program and serve as VP of clinical development.
After posting sinking response rates, Nektar unveiled new results for its NKTR-214 and Opdivo melanoma therapy that showed rates holding just steady.
Nektar is a multibillion-dollar biotech with most of its value tied to a single drug—and that drug doesn’t work, claims Plainview.
Martin Shkreli, infamous for his combative tweets and general "insolent" demeanor, may be blogging biopharma tips from prison.
Nektar’s much-anticipated data from a study pairing its NKTR-214 with Bristol-Myers Squibb’s Opdivo have resulted in a lot of head-scratching.
Syndax’s shares slid after an ASCO abstract revealed lackluster data with entinostat, but it's forging ahead with a new combination study with Nektar.
The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers.